About TreeFRog Therapeutics
We bring together biophysicists, stem cell biologists & bioproduction engineers around the motto
"Cell Therapy for All"
THE VISION
TreeFrog Therapeutics was created to provide access to safe, efficient and affordable cell therapies for millions of patients.
TreeFrog Today
Hyper-growth since incorporation in 2018
0
+
team
$
0
M
raised since 2018
0
patents
0
sites worldwilde
EXecutive team
Frédéric Desdouits, PhD
Chief Executive Officer
Kévin Alessandri, PhD
Co-Founder, Chief Technology Officer
Maxime Feyeux, PhD
Co-Founder, Chief Scientific Officer
Marie Daniel Catoire, MBA
General SECRETARY
Gabriel Chaigneau, MSc
Chief Finance officer
Myriam Makhloufi, MSc
BUSINESS STRATEGY OFFICER
Michael Lanero Fidalgo, MBA
Chief Operating Officer
Board members
Elsy Boglioli
Chair, INDEPENDENT board MEMBER
Frédéric Desdouits, PhD
Chief Executive Officer
Kévin Alessandri, PhD
Co-Founder, Chief Technology Officer
Melissa Carpenter, PhD
independEnt board MEMBER
Peter Nell, PhD
independEnt board MEMBER
Laurent Higueret
BPI Large Venture
Pete Zippelius
Leonard Green & Partners
Guilhem de Vregille
Xange
Marine Choplain
ObservER, Bpifrance
Bryan Campbell
Observer, BRISTOL-MYERS SQUIBB
Fabienne Mazeau
Observer, AQUITI Gestion
Maxime Feyeux, PhD
Observer, Co-Founder and CSO
SCIENTIFIC ADVISORY BOARD
Prof. Peter Andrews
Emeritus Professor, University of Sheffield, UK
Prof. L. Mahadevan
Professor of Physics, de Valpine Professor of Applied Mathematics, Professor of Organismic and Evolutionary Biology, Harvard University, USA
Marta Shahbazi, PhD
Group Leader, MRC Laboratory of Molecular Biology (LMB) Cambridge, UK
Justin Eyquem, PhD
Assistant Professor, University of California San Francisco, Co-founder of Mnemo Therapeutics, USA
Shin Kawamata, MD, PhD
Director, Research and Development Center for Cell Therapy, FBRI Kobe, Japan
Pierre Nassoy, PhD
Research Director, CNRS,
co-inventor of C-SteM technology, Bordeaux, France
They trust us
Our partners
Scientific COLLABORATions
INvestors
Public funding
EARLY SUPPORT
TreeFrog Therapeutics is receiving funding from the European Union’s Horizon 2020 research and innovation program through the SME Instrument Phase 2 under grant agreement n° SME 881113.
La Région et l’Union européenne soutiennent le projet CHAMBERLAN dans le cadre du « Programme Opérationnel FEDER/FSE Aquitaine 2014-2020 » en conformité avec la règlementation européenne en matière de Fonds européens structurels et d’investissement (FESI).